Gender and Antidepressants

Principles of Gender-Specific Medicine

Volumn 2, Issue , 2004, Pages 860-868

  Bies, Robert R ^a   Bigos, Kristin L ^a   Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38349134490     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50350-9     Document Type: Chapter

References (109)

1. Schmucker DL, Vessell ES Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther 1993, 54:11-15.
2. Dawkins K, Potter WZ Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: Focus on women. Psychopharmacol Bull. 1991, 27:417-426.
3. Harris RZ, Benet LZ, Schwartz JB Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995, 50:222-239.
4. Hamilton J, Parry B Sex related differences in clinical drug response: Implications for women's health. J Am Med Womens Assoc 1983, 38:126-132.
5. Stewart DE Are there special considerations in the prescription of serotonin reuptake inhibitors for women. Can J Psychiatry 1998, 43:900-904.
6. Cortecchio M, Kreiger N, Darlington G, Steingart S Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000, 151:951-957.
7. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993, 50:85-94.
8. Rapaport MH, Thompson PM, Kelsoe JR, et al. Gender differences in outpatient research subjects with affective disorders: A comparison of descriptive variables. J Clin Psychiatry 1995, 56:67-72.
9. Hirschfeld RMA, Russell JM Assessment of treatment of suicidal patients. N Engl J Med 1997, 337:910-915.
10. Physicians' Desk Reference 2002, Medical Economics and Thomson Health Care, Montvale, NJ.
11. Thompson DS, Kirshner MA, Klug TL et al. (in press). Effect of fluoxetine treatment on the 2:16a-hydroxyestrone ratio in young women. Ther Drug Monitoring.
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.
13. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002, 287:591-597.
14. Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines and antihistamines. Am J Epidemiol 1999, 150:861-868.
15. Grossman MI, Kirsner JB, Gillespie IA Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 1963, 45:14-26.
16. Hutson WR, Roehrkasse RL, Wald A Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989, 96:11-17.
17. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: The effect of the menstrual cycle. Gastroenterology 1981, 80:1497-1500.
18. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 2001, 41:770-778.
19. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp Ther 1980, 215:86-91.
20. Greenblatt DJ, Divoll M, Abernethy DR, Shader RI Physiologic changes in old age: Relation to altered drug disposition. J Am Geriatr Soc 1982, 30(Suppl):S6-S10.
21. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: Effect of age, gender, and obesity. Clin Pharmacol Ther 1987, 42:193.
22. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokineitcs of single and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995, 35:876-884.
23. Kristensen CB Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983, 34:689-694.
24. Rowland M, Tozer T Elimination concepts. Clinical Pharmacokinetics: Concepts and Applications 1989, 170. Lea & Febiger, Malvern, PA. 2nd Edition. M. Rowland, T. Tozer (Eds.).
25. Meibohm B, Beierle I, Deredorf H How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 2002, 41:329-342.
26. Schuetz EG, Furuya KN, Schuetz JD Interindividual variation in expression of P-glycoprotein in normal liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995, 275:1011-1018.
27. Barbhaiya RH, Buch AB, Green DS A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996, 16:19-25.
28. Ronfeld RA, Tremaine LM, Wilner KD Pharmacokinetics of sertraline and its N-dimethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997, 32:22-30.
29. Reis M, Olsson G, Carlsson B, et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002, 22:406-413.
30. Preskorn SH Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997, 32:1-21.
31. Hartter S, Wetzel H, Hammes E, et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monitoring 1998, 20:446-469.
32. Timmer CJ, Paanakker JE, Van Hal HJM Pharmacokinetics of mirtazapine from orally administered tablets: Influence of gender, age and treatment regimen. Hum Psychopharmacol 1996, 11:497-509.
33. Timmer CJ, Sitsen JM, Delbressine LP Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000, 38:461-474.
34. Mundo E, Pirola R, Bellodi L, et al. Are gender differences in antiobsessional response related to different clomipramine metabolism?. J Clin Psychopharmacol 2002, 22:341-342.
35. Dahl ML, Bertilsson L, Nordin C Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype. Psychopharmacology 1996, 123:315-319.
36. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI Effect of age and gender on disposition of temazepam. J Pharm Sci 1981, 10:1104-1107.
37. Pollock BG, Wylie M, Stack JA, et al. Inhibition of CYP1A2 mediated metabolism by estrogen replacement therapy in post-menopausal women. J Clin Pharmacol 1999, 39:936-940.
38. Ford JM, Truman CA, Wilcock GK, Roberts CJ Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993, 53:691-695.
39. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000, 157:1445-1452.
40. Domecq C, Naranjo C, Ruiz I, Busto U Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980, 18:362-366.
41. Gordon JH, Borison RL, Diamond BI Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry 1980, 15:389-396.
42. Halbreich U, Rojansky N, Palter S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995, 37:434-441.
43. Halbreich U Role of estrogen in postmenopausal depression. Neurology 1997, 48(Suppl 7):S16-S19.
44. Halbreich U, Smoller JW Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997, 58:399-402.
45. Halbreich U, Kahn LS Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001, 15:797-817.
46. Joffe H, Cohen LS Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge?. Biol Psychiatry 1998, 44:798-811.
47. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2a receptor binding: A PET study. Biol Psychiatry 2000, 48:854-860.
48. Duman RS, Heninger GR, Nestler EJ Molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
49. Nibuya N, Nestler EJ, Duman RS Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996, 16:2365-2372.
50. Belcher SM, Zsarnovszky A Estrogenic actions in the brain: Estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001, 299:408-414.
51. Nibuya M, Morinobu S, Duman RS Regulation of BDNF and trkB mRNA: in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7439-7547.
52. Sohrabji F, Miranda RC, Toran-Allerand CD Estrogen differentially regulates estrogens and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994, 14:459-471.
53. 2A receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995, 54:15-20.
54. Sterlund MK, Overstreet DH, Hurd YL The Flinders Sensitive Line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17β-estradiol. Mol Brain Res 1999, 74:158-166.
55. Wissink S, van der Burg B, Katzenellenbogen BS, van der Saag PT Synergistic activation of the serotonin-1A receptor by nuclear factor-κB. Mol Endocrinol 2001, 15:543-552.
56. Palinkas LA, Barrett-Connor E Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992, 80:30-36.
57. Zweifel JE, O'Brien WH A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997, 22:189-212.
58. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997, 5:97-106.
59. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993, 21:30-34.
60. Thase ME, Frank E, Kornstein SG, Yonkers KA Gender Differences in Response to Treatments of Depression. Gender and Its Effect on Psychopathology 2000, 103-125. American Psychiatric Press, Washington DC. E. Frank (Ed.).
61. Davidson J, Pelton S Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986, 17:87-95.
62. West ED, Dally PJ Effect of iproniazid in depressive syndromes. BMJ 1959, 1:1491.
63. Raskin A Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974, 159:120-130.
64. Okiishi CG, Paradiso S, Robinson RG Gender differences in depression associated with neurologic illness: Clinical correlates and pharmacologic response. J Gender Specific Med 2001, 4:65-72.
65. Hamilton JA, Grant M, Jensvold MF Sex and Treatment of Depressions: When Does It Matter?. Psychopharmacology and Women: Sex, Gender, and Hormones 1996, 241-260. Institute for Womens Health, Washington DC. M.F. Jensvold, U. Halbreich (Eds.).
66. Martenyi F, Dossenbach M, Mraz K, Metcalfe S Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001, 11:227-232.
67. Bogetto F, Bellino S, Revello RB, Patria L Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: A clinical investigation. CNS Drugs 2002, 16:273-283.
68. Thompson DS, Pollock BG Psychotropic metabolism: Gender related issues. Psychiatric Times 2001, 18:1.
69. Demers LM Premenstrual, Postpartum, and Menopausal Mood Disorders 1989, Urban and Schwarzenberg, Baltimore.
70. Steiner M, Korzekwa M, Lamont J, Wilkins A Intermittent fluoxetine dosing in the treatment of women with premanstrual dysphoria. Psychopharmacol Bull 1997, 33:771-774.
71. Sundblad C, Hedberg MA, Ericksson E Clomipramine administered during the luteal phase reduces the symptoms of pre-menstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology 1993, 9:133-145.
72. Young SA, Hurt PH, Benedek DM, Howard RS Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998, 59:76-80.
73. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmacol 1998, 18:390-398.
74. Alpay FB, Turhan NO Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. Int J Fertil Womens Med 2001, 46:228-231.
75. Kimmel S, Gonsalves L, Youngs D, Gidwani G Fluctuating levels of antidepressants premenstrually. J Psychosom Obstet Gynaecol 1992, 13:277-280.
76. Lane JD, Steege JF, Rupp SL, Kuhn CM Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 1992, 43:543-546.
77. Kashuba ADM, Nafziger AN Physiologic changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998, 34:203-218.
78. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prazac). JAMA 1993, 269:2246-2248.
79. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999, 282:1264-1269.
80. Wisner KL, Zarin D, Holboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000, 157:1933-1940.
81. Bologa M, Tang B, Klein J, et al. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991, 257:735-740.
82. Schou M, Weinstein MR Problems of lithium maintenance treatment during pregnancy, delivery and lactation. Agressolgie 1980, 21(A):7-9.
83. Wisner KL, Perel J, Wheeler SB Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993, 150:1541-1542.
84. Aldridge A, Bailey J, Neims AH The disposition of caffeine during and after pregnancy. Semin Perinatol 1981, 15:310-314.
85. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996, 10:285-294.
86. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal, use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 1998, 279:609-610.
87. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
88. Ericsson A, Kallen B, Wiholm B Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55:503-508.
89. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336:258-262.
90. Loebstein R, Koren G Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: The Motherisk experience. J Psychiatry Neurosci 1997, 22:192-196.
91. Merkatz RB, Temple R, Subel S, et al. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med 1993, 329:292-296.
92. National Institutes of Health Opportunities for Researchon Women's Health 1992, Publication 92-3457A, National Institutes of Health, Washington DC.
93. Lecrubier Y, Clerc G, Didi R, Kieser M Efficacy of St. John's wort extract WS 5570 in major depression: A double-blind, placebo-controlled trial. Am J Psychiatry 2002, 159:1361-1366.
94. van Gurp G, Meterissian GB, Haiek LN, et al. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physican 2002, 48:905-912.
95. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial. JAMA 2002, 287:1807-1814. Hypericum Depression Trial Study Group.
96. Armstrong SC, Cozza KL, Cole MA Consultation-liaison psychiatry drug-drug interactions update. Psychosomatics 2000, 5:310-314.
97. Cohen LG, Biederman J, Wilens T, et al. Desipramine clearance in children and adolescents: Absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1999, 38:79-85.
98. Merle Y, Mentre F Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring. J Pharmacokinet Biopharm 1999, 27:85-101.
99. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacol therapy 1996, 16:915-923.
100. Mahmood I, Sahajwalla C Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999, 36:277-287.
101. Gammans RE, Westrick ML, Shea JP, et al. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 1989, 29:72-78.
102. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1994, 15:1181-1182.
103. Mundo E, Bareggi SR, Pirola R, Bellodi L Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable?. Biol Psychiatry 1999, 45:290-294.
104. Bruder GE, Stewart JW, Tenke CE, et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry 2001, 49:416-425.
105. Lanctot KL, Herrmann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 2002, 17:531-541.
106. Naranjo CA, Bremner KE, Lanctot KL Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995, 90:87-99.
107. Belcher SM, Zsarnovszky A Estrogenic actions in the brain: Estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001, 299:408-414.
108. Shaldubina A, Agan G, Belmaker RH The mechanism of lithium action: State of the art, ten years later. Prog Neuropsychopharmacol Biol. Psychiatry 2001, 25:855-866.
109. 7 receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons. Neuroscience 2001, 102:361-367.